Blood sugar, weight, cholesterol and the liver.
In a double-blind crossover trial of thirty-one people with type 1 diabetes and kidney disease, 24 weeks of ursodeoxycholic acid did not reduce urine albumin compared with placebo, despite promising results in…
In a phase 2 trial published Oct. 26, 2026, in Cell Metabolism, UBT251, a weekly shot that acts on three gut hormones, lowered HbA1c by up to 2.16% at 24 weeks in…
A meta-analysis of 85 randomized trials, published Oct. 24, 2026, in JAMA, found that SGLT2 inhibitors raised hemoglobin by 0.60 g/dL more than control, a small increase whose clinical meaning is still…
A Medicare study published Oct. 1, 2026, in JAMA Network Open found that after the 2019 diabetes guideline update, SGLT2 inhibitor fills rose 11.4 percentage points in the patients it targeted, more…
In adults with type 2 diabetes starting a second medicine after metformin, SGLT-2 inhibitors or GLP-1 drugs lowered the five-year risk of kidney decline vs. DPP-4 inhibitors in people with protein in…
A Korean study of 209 698 adults with type 2 diabetes, published Oct. 1, 2026, in JAMA Network Open, linked quitting smoking for 8 or more years to a lower risk of…
In a phase 3 trial published Oct. 30, 2026, in The Lancet Diabetes & Endocrinology, Japanese adults with obesity disease who took orforglipron, a once-daily GLP-1 pill, lost 5.9% to 8.7% of…
The LITMUS study, published Oct. 31, 2026, in The Lancet, compared 30 non-invasive tests against liver biopsy in 1590 adults with fatty liver disease. Multimarker panels did best, led by a protein…
In a placebo-controlled crossover trial of 15 people with fatty liver disease, 6 weeks of a drug that blocks the first step of fructose metabolism improved the liver's response to insulin and…
A US records study of 70 257 adults with schizophrenia and type 2 diabetes, published in November 2026 in The Lancet Psychiatry, linked starting a GLP-1 drug to fewer psychiatric hospitalizations than…
In older US adults with fatty liver disease, starting a GLP-1 drug was linked to lower risks of liver decompensation (hazard ratio 0.72) and death (0.55), but not of major heart events,…
A US claims study of 27,650 adults with laboratory-confirmed diabetes, published Oct. 5, 2026, in Diabetes Care, found that only 66.6% received both a diagnosis code and treatment within a year, and…
In a UK registry study of 4,477 people with cystic fibrosis-related diabetes, published Oct. 26, 2026, in Diabetes Care, death rates rose step by step with higher HbA1c, up to a rate…
In a trial at US primary care practices, published Oct. 14, 2026, in NEJM, adults with type 2 diabetes not using insulin who wore a continuous glucose monitor lowered their A1c from…
In 701 adults with type 1 diabetes and no prior heart disease, carotid plaques were found in 40.4%. Over almost six years, having three or more plaques was linked to a higher…
A study of 1022 people after weight-loss surgery, published in October 2026 in The American Journal of Clinical Nutrition, found that men and postmenopausal women lost a larger share of lean mass…
In a small randomized trial of 33 hospitalized patients with type 2 diabetes using glucose sensors, a low-carbohydrate diet with almonds kept night-time blood sugar in range 98.51% of the time, vs.…
In a German cohort published Oct. 30, 2026, in The Lancet Diabetes & Endocrinology, adults recently diagnosed with type 1 diabetes fell into three subtypes. A 'mixed' subtype was diagnosed 6.1 years…
In a phase 2 trial published Oct. 28, 2026, in Diabetes Care, adults with type 1 diabetes and overweight or obesity who took acmopatide lost 3.3% to 6.7% of their body weight…
In a 12-week randomized trial of 160 adults with type 2 diabetes, people who ate intact whole grains ended with an HbA1c 2.2 mmol/mol lower than people who ate the same grains…
